Hematology/Oncology

Top Story

FDA approves Tafinlar plus Mekinist for BRAF V600E–mutant non–small cell lung cancer

June 22, 2017

The FDA approved use of dabrafenib in combination with trametinib for treatment of patients with metastatic non–small cell lung cancer whose tumors harbor BRAF V600E mutations, according to the agents’ manufacturer.

The combination of dabrafenib (Tafinlar, Novartis) — a BRAF inhibitor — and trametinib (Mekinist, Novartis), a MEK1/2 inhibitor — is the first targeted treatment approved in the United States specifically for patients with BRAF V600E–positive metastatic NSCLC.

Meeting NewsVideo

VIDEO: Updated KEYNOTE-024 results raise question in sequencing of lung cancer treatments

June 22, 2017
CHICAGO — Hossein Borghaei, DO, chief of the division of thoracic medical oncology at Fox Chase Cancer Center, discusses the updated KEYNOTE-024 data and how the…
FDA News

FDA approves Rituxan Hycela subcutaneous injection for blood cancers

June 22, 2017
The FDA approved Rituxan Hycela subcutaneous injection to treat three blood cancers. Rituxan Hycela (Genentech) — a combination of rituximab (Rituxan; Genentech…

Senate health care bill takes slower approach to House bill, expert concerns persist

June 22, 2017
The Senate health care bill, released to the public today, maintains much from the version the House passed May 4, 2017, but presents some key changes such as a slower…
In the Journals Plus

Cost of hospital-based end-of-life care high for elderly with brain tumors

June 22, 2017
Hospital-based end-of-life care for elderly patients with malignant brain tumors is associated with up to $16,000 in expenses, according to a research letter published…
More News Headlines »
CME

Immune Checkpoint Inhibition for Melanoma Management: When, What, How, and in Whom?

This activity is supported by educational grants from Bristol-Myers Squibb and Merck & Co., Inc.

It is estimated that 76,380 new cases of melanoma will be diagnosed in the United Stated in 2017, with approximately…
More »
Video
Meeting News

VIDEO: Results from MONALEESA-2 represent ‘exciting update’ for metastatic breast cancer

June 18, 2017
More »
Featured
ASCO Annual Meeting

ASCO Annual Meeting

CME

Bridging the Gap from Knowledge to Practice in CRPC

This activity is supported by educational funding provided by AbbVie Inc.; Astellas Scientific and Medical Affairs, Inc. and Medivation; and Sanofi US.

The selection of therapy for patients with castration-resistant prostate cancer (CRPC) remains challenging. Review…
More »
Current Issues
View the Current Issue
HemOnc Today
Advertisement
Advertisement